Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry.
José Pablo LeoneBernardo A LeoneNabihah TayobMichael J HassettJulieta LeoneRachel A FreedmanSara M TolaneyEric P WinerCarlos T VallejoNancy U LinPublished in: Breast cancer research and treatment (2021)
In stage III breast cancer, the risk of BCSM at 20 years is very high and remains important even beyond the first 5 years in both HR-positive and HR-negative disease. Late BCSM depends on traditional clinicopathologic factors.